675122-48-2

Basic information

• Product Name: Benzenamine, 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)- (9CI)
• Synonyms: Benzenamine, 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)- (9CI)
• CAS NO: 675122-48-2
• Molecular Formula: C₁₀H₁₃N₅
• Molecular Weight: 203.24372
• Product Categories: ETHYL
• Mol File: 675122-48-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenamine, 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)- (9CI)(675122-48-2)
• EPA Substance Registry System: Benzenamine, 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)- (9CI)(675122-48-2)

Safety Data

• Hazardous Substances Data: 675122-48-2(Hazardous Substances Data)

Upstream product

• 675122-47-1 1-methyl-5-(3-nitro-5-vinylphenyl)-1H-tetraazole 
• 121-92-6 3-nitrobenzoic acid 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 51339-40-3 3-bromo-5-nitrobenzoyl chloride 
• 675122-46-0 5-(3-bromo-5-nitrophenyl)-1-methyl-1H-tetraazole 
• 90050-52-5 3-bromo-N-methyl-5-nitrobenzamide 

Downstream Products

• 675122-49-3 phenyl 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenylcarbamate 
• 852661-64-4 N-((1R,2S)-3-{cyclohexyl[3-(4-fluorophenyl)propyl]amino}-2-hydroxy-1-methylpropyl)-N'-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 852660-57-2 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)amino]methyl}cyclohexyl)urea 
• 852660-52-7 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino]methyl}cyclohexyl)urea 
• 852660-89-0 N-{(1R,3R,4S)-4-{[[2,2-dimethyl-3-(4-fluorophenyl)propyl](methyl)amino]methyl}-3-[({[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]amino}carbonyl)amino]cyclohexyl}-N-methylacetamide 

Relevant articles and documents

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis

Conformational analysis of trans-1,2-disubstituted cyclohexane CCR3 antagonist 2 revealed that the cyclohexane linker could be replaced by an acyclic syn-α-methyl-β-hydroxypropyl linker. Synthesis and biological evaluation of mono- and disubstituted propyl linkers support this conformational correlation. It was also found that the α-methyl group to the urea lowered protein binding and that the β-hydroxyl group lowered affinity for CYP2D6. Ab initio calculations show that the α-methyl group governs the spatial orientation of three key functionalities within the molecule. α-Methyl-β-hydroxypropyl urea 31 with a chemotaxis IC50 = 38 pM for eosinophils was chosen to enter clinical development for the treatment of asthma.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Substituted fused bicyclic amines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

N-substituted heterocyclic amines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY.

The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.